Advertisement
UK markets close in 4 hours 14 minutes

  • FTSE 100

    8,087.76
    +47.38 (+0.59%)
     

  • FTSE 250

    19,694.13
    -25.24 (-0.13%)
     

  • AIM

    754.62
    -0.07 (-0.01%)
     

  • GBP/EUR

    1.1661
    +0.0016 (+0.14%)
     

  • GBP/USD

    1.2507
    +0.0045 (+0.36%)
     

  • Bitcoin GBP

    50,878.62
    -2,221.26 (-4.18%)
     

  • CMC Crypto 200

    1,349.37
    -33.21 (-2.40%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    82.82
    +0.01 (+0.01%)
     

  • GOLD FUTURES

    2,340.10
    +1.70 (+0.07%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,954.15
    -134.55 (-0.74%)
     

  • CAC 40

    8,016.74
    -75.12 (-0.93%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.2%

Zacks Equity Research

Heron Therapeutics, Inc. HRTX was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $17.61–$21.39 in the past one-month time frame, witnessed a sharp increase yesterday.

The move came after the company announced positive topline results from phase 3b clinical study of HTX-011 in total knee arthroplasty.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Heron Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Heron Therapeutics, Inc. Price

Heron Therapeutics, Inc. Price
Heron Therapeutics, Inc. Price

Heron Therapeutics, Inc. price | Heron Therapeutics, Inc. Quote

ADVERTISEMENT

Investors interested in the Medical - Drugs industry may consider FibroGen, Inc. FGEN, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is HRTX going up? Or down? Predict to see what others think:Up or Down

Biggest Tech Breakthrough in a Generation
 
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.

See 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Heron Therapeutics, Inc. (HRTX) : Free Stock Analysis Report
 
FibroGen, Inc (FGEN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research